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estimated $24,940,983,900.00 ($24.9B) in wages are lost from 43,750 years of foregone 
employment, yielding a total ten year cGvHD cost burden of $30,214,063,841.50 
($30.2B). ConClusions: The human capital perspective should be considered in 
making policy recommendations for coverage of cGvHD treatments that affect those, 
including Central and South American patients, who survice acute complications 
of allogeneic transplantation.
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objeCtives: To conduct a cost-effectiveness analysis of romiplostim as first-line 
ITP treatment in adult splenectomised patients who are refractory to other treat-
ments and as second-line treatment in adult non-splenectomised patients for 
whom surgery is contra-indicated vs. eltrombopag. Methods: A Markov model 
with embedded decision tree containing three health status (platelets≥ 50× 109/L; 
platelets< 50× 109/L; and dead) was developed from a Colombian Health Ministry 
perspective and evaluated at 4-week cycles over a lifetime horizon. Efficacy was 
characterized by initial response; mean time to response, and duration of response 
and was estimated from literature review. Used resources and treatment patterns 
were obtained by a modified Delphi panel from a group of four hematologist. Costs 
include drug administration, visits, laboratory tests, rescue therapy, intracranial, GI 
and gynecological bleeding. Social Security costs (ISS+30) are used for procedures, 
visits and laboratory tests; and SISMED-2014 prices for drugs. Clinical benefits and 
costs are discounted 5% per annum. Results: Total expected treatment cost for 
romiplostim arm was $1,276,302,002 (romiplostim cost $408,991,91; subsequent 
treatment lines $4,612,365; rescue therapy (IVIg and IV steroids) $859,929,341; and 
bleedings $2,768,379) vs. $1,315,173,138 for eltrombopag arm (eltrombopag cost 
$191,795,316; subsequent treatment lines $5,836,389; rescue therapy $1,113,981,314; 
and bleedings $3,560,119). Use of romiplostim, compared with eltrombopag, 
increased 4.46 years response duration, prevented 4.5 bleeding episodes and 
1.5 admissions over a lifetime horizon. Romiplostim proves to be the dominant 
approach compared with eltrombopag. ConClusions: Use of romiplostim in the 
ITP treatment pathway, compared with eltrombopag, improves clinical outcomes, 
by increasing and maintaining platelet count, reducing bleeding events and rescue 
therapy need. These benefits generate cost savings and positioning romiplostim 
as a dominant approach.
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objeCtives: Present a systematic review of efficacy, effectiveness and safety 
of pharmacological treatments (sibutramine and orlistat) used in obesity treat-
ment and performs a cost-effectiveness analysis comparing: (a) Diet; (b) diet plus 
sibutramine and (c) diet plus orlistat under the public health system perspec-
tive. Methods: A systematic review of literature produced the estimates of co-
morbidities risks and disease progression with and without the interventions. 
A Markov model that simulates related obesity comorbidities as chronicle heart 
disease and diabetes mellitus was build. Discount rate assumed was 5% and the 
outcome data was taken from international literature and was measured by QALY. 
Direct cost was calculated by the authors using data from public health system 
databases, as well as in related cost studies made in Brazil. PARTIAL Results: 
The systematic review has initially provided results of effectiveness of the inter-
ventions. Weight loss values after one year of treatment ranged from -6,35 kg to 
sibutramine 15mg and -2,89kg to standard care (only Diet). All patient gain weight 
after intervention in a rate of 0,385kg/month (first four years), and at 1kg/year in 
the next years. Annual costs of co-morbidities were estimated in U$7,017.00 to 
infarction and U$1,335.00 to diabetes. ConClusions: More data will be collected, 
to complement this preliminary serving as input to complete de cost-effectiveness 
model.
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objeCtives: To evaluate costs associated with the use of dexmedetomidine 
in comparison with conventional clinical practice in Portugal in intensive care 
unit (ICU) patients through a cost-minimisation and a budget impact analy-
sis. Methods: The population consisted of ICU ventilated patients requiring a 
mild to moderate level of sedation. Time spent at ICU was estimated based on a 
head-to-head published clinical trial (PRODEX) comparing the two sedatives. The 
time horizon was inpatient stay at ICU considering three periods: mechanical 
ventilation, non-mechanical ventilation and off ventilator. The analysis considered 
the Portuguese National Health Service perspective and only included ICU stay and 
sedative costs, which were extracted from Portuguese official sources (2014 prices). 
Sensitivity analyses were performed. Results: The estimated mean costs per ICU 
patient discharge were € 13,950 for dexmedetomidine and € 14,711 for propofol 
resulting in a cost-saving of € 761 per patient. Sensitivity analysis confirmed sav-
ings upon the use of dexmedetomidine ranging from € 598 to € 1,418. Introducing 
dexmedetomidine in hospitals for sedation in ICU would result in yearly savings of 
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objeCtives: Estimate direct and indirect costs generated by eight diseases related 
to O&O in Mexican population for the period 1999-2023. Methods: Data on diabe-
tes, cardiovascular disorders (CVD), osteoartritis, and malignant tumors (esopha-
gus, pancreas, breast, cervix, colo-rectal) are analyzed for 2004-2013. Cost of illness 
approach was used for direct cost estimates; Indirect costs are estimated by the 
human capital approach that includes lost income for premature death (LIPD), tem-
porary disability subsidies (TDS), permanent disability pension (PDP) and opportu-
nity cost for the non-medical care giver (OCC). Results: Annual average direct costs 
generated by selected diseases related to O&O represented 17% of the total public 
medical care expenditure (0.1% of GDP) of 2013. Diabetes and CVD contributed with 
80% of such costs. Annual average indirect costs represented 0.2% of GDP of 2013 and 
are dominated by LIPD (64%) followed by PDP (19%) and OCC (10%). ConClusions: 
Findings show the need of continue efforts to address the challenge posed by O&O 
for both the Mexican health care system in terms of financial sustainability and 
the Mexican society as a whole in terms of significant reductions in productivity 
in the short and midterms. Of particular relevance is the recent implementation 
of the National Strategy to Prevent and Control O&O and Diabetes which should 
be monitored and evaluated in order to document effectiveness of public policy 
interventions in the O&O arena for the Mexican case.
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objeCtives: This study evaluated the cost-effectiveness of pegvisomant com-
pared to octreotide-LAR and the incremental Budget Impact Analysis (iBIA) from 
the public perspective in São Paulo State Health Secretariat (SHS/SP). Methods: 
The economic evaluation assumed octreotide-LAR to be first line treatment as 
(recommended to acromegaly Ministry of Health Brazilian guideline). In certain 
clinical conditions patients who fail to achieve biochemical control will receive 
octreotide-LAR staggered dose (off-label use). This population was used for the 
analysis, and compared to a population of patients with acromegaly treated with 
pegvisomant. To estimate costs and treatment outcomes, a Markov model was 
developed, representing the control rate of patients treated with pegvisomant or 
maintained dose staggered octreotide-LAR. All patients entering the model who 
were unresponsive to the maximum octreotide-LAR dose based on the transition 
risk and according to control or non-control of disease, patients could transition 
to one of the following states: control; non-control and death (absorbing state). 
A time horizon of 35 years was assumed and a discount rate of 5% per annum 
was applied. The outcomes of interest were: “years of life” and “years living with 
disease control”. To estimated number of SHS/SP eligible patients, the epidemio-
logical demand method was applied that resulted in 210 patients (2015). Results: 
The iBIA was estimated to increase by 24.87% of current spending, if pegvisomant 
is reimbursed by the government in SHS/SP. for “year of life” and “years living 
with disease control” were 0.46 and 1.37 years, respectively, and for pegvisomant 
saving BRL 313,599.84. The final result did not change; the sensitivity analysis 
demonstrated the model robustness. ConClusions: Pegvisomant is a dominant 
technology compared to octreotide-LAR under the SHS/SP and it may represent a 
feasible treatment option for patients with acromegaly in the acromegaly treat-
ment in SHS/SP.
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objeCtives: With advances to treating acute graft-versus-host-disease (aGvHD), 
chronic graft-versus-host disease (cGvHD) has become a focus of morbidity fol-
lowing allogeneic hematopoietic stem cell transplantion. Given that cGvHD often 
presents years following a transplant, our objective was to estimate its burden 
of cost based on published estimates of incidence, morbidity, lost work time and 
survivorship. Methods: Treatment pathways and adverse events were evaluated 
in terms of direct cost from published sources. Additional cost estimates for read-
mission and follow-up care were annualized and compared between non-cGvHD 
patients and grades I-IV of cGvHD over a 5 year horizon, based on studies conducted 
in the United States and United Kingdom. Indirect costs (or benefits) were calculated 
based on age-adjusted United States Census Bureau reported average wages, wage 
growth and the probability that with illness these would be foregone. Results: 
The total burden of cost from cGvHD is far more poignant when viewing long-term 
and morbidity, mortality and consequent wages foregone, even as compared with 
the cost of transplant and normative follow-up. Relapse due to primary disease 
(29%) and cGvHD (22%) were reported by the literature to be the leading causes 
of premature mortality. This is important in the counter-factual scenario where 
patients might have returned to normal daily activities. With the burden of cost for 
cGvHD presented as a summation of direct and indirect components, aggressive 
upfront treatments may have a potential to reduce long-term complications and 
maintain the ability to return to daily functioning. From the societal perspective, an 
